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ABSTRACT 50 
OBJECTIVE: We aimed to summarize key articles published between 2011 and 51 
2015 on the treatment of (recurrent) acute otitis media, otitis media with effusion, 52 
tympanostomy tube otorrhea, chronic suppurative otitis media and complications of 53 
otitis media, and their implications for clinical practice. 54 
DATA SOURCES: PubMed, Ovid Medline, the Cochrane Library, and Clinical 55 
Evidence (BMJ Publishing).  56 
REVIEW METHODS: All types of articles related to otitis media treatment and 57 
complications between January 2011 and March 2015 were identified. A total of 58 
1122 potential related articles were reviewed by the panel members; 118 relevant 59 
articles were ultimately included in this summary. 60 
CONCLUSIONS: Recent literature and guidelines emphasize accurate diagnosis of 61 
acute otitis media and optimal management of ear pain. Watchful waiting is optional 62 
in mild to moderate acute otitis media; antibiotics do shorten symptoms and duration 63 
of middle ear effusion. The additive benefit of adenoidectomy to tympanostomy 64 
tubes in recurrent acute otitis media and otitis media with effusion is controversial 65 
and age-dependent. Topical antibiotic is the treatment of choice in acute tube 66 
otorrhea. Symptomatic hearing loss due to persistent otitis media with effusion is 67 
best treated with tympanostomy tubes.  Novel molecular and biomaterial treatments 68 
as adjuvants to surgical closure of eardrum perforations seem promising. There is 69 
insufficient evidence to support the use of complementary and alternative 70 
treatments.  71 
IMPLICATIONS FOR PRACTICE: Emphasis on accurate diagnosis of otitis media, 72 
in its various forms, is important to reduce over-diagnosis, over-treatment and 73 
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antibiotic resistance. Children at risk for otitis media and its complications deserve 74 
special attention.     75 
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INTRODUCTION 76 
Otitis media (OM) is a leading cause of health care visits, antibiotic 77 
prescriptions and surgery1,2.  Its complications and sequelae are important causes of 78 
preventable hearing loss, particularly in developing countries. Reducing OM burden 79 
is warranted, and decision making should be based on the best available evidence.   80 
 Our ‘Treatment and Complications’  Panel consisted of 11 clinician scientists 81 
in the field of OM who convened at the 2015 Post-Symposium Research 82 
Conference, following the 18th International Symposium on Recent Advances in 83 
Otitis Media, National Harbor, MD. We focused on articles on the treatment of OM 84 
and its complications which were published since the last Panel report3, and 85 
reviewed their implications for clinical practice. This paper summarizes our main 86 
findings. 87 
 88 
 89 
  90 
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METHODS 91 
 Panel members were assigned to review the literature on the management of 92 
one of the following disease entities: acute otitis media (AOM), recurrent AOM 93 
(rAOM), otitis media with effusion (OME), tympanostomy tube (TT) otorrhea, chronic 94 
suppurative otitis media (CSOM), and OM-related complications.  95 
Each panel member designed a topic-specific key-word search strategy for 96 
the various electronic databases, including PubMed, Ovid Medline, the Cochrane 97 
Library and Clinical Evidence (BMJ Publishing).  Databases were searched from 98 
6/1/2011 through 3/31/2015, restricted to articles with at least an abstract published 99 
in the English language. Publications cited in the previous review3 were excluded. 100 
Searches were supplemented by additional relevant articles (including evidence-101 
based practice guidelines) identified by members during discussion at the panel 102 
meeting.  103 
   We retrieved a total of 1935 records from the initial electronic database 104 
searches, of which 813 were excluded because of irrelevant title.  Of 1122 articles 105 
retrieved for more detailed evaluation, 116 articles remained after excluding 106 
duplicates, irrelevant articles, narrative (non-systematic) review articles, 107 
commentaries and letters to the editor. Finally, after adding two more articles from 108 
reference lists, 118 articles were included in this manuscript after final discussion.  109 
  110 
  111 
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DISCUSSION 112 
Acute Otitis Media (Table 1) 113 
A high-quality placebo-controlled trial performed by Tapiainen4, found that oral 114 
antibiotics shortened the period with middle ear effusion (MEE) after AOM. This trial 115 
was included in a 2015 Cochrane review update5, which showed that oral antibiotics 116 
for AOM reduce the proportion of children with abnormal tympanograms at 2-4 and 117 
6-8 weeks, but not at 3 months. Both this review5 and a 2014 BMJ Clinical Evidence 118 
review6 concluded that “antibiotic treatment reduces AOM symptoms more quickly 119 
than placebo, but this benefit needs to be weighed against the increased risk of 120 
adverse events such as vomiting, diarrhea or rash”. 121 
Type of Antibiotic Treatment 122 
The 2014 BMJ review6 summarized the evidence on antibiotic choice in 123 
children with AOM and concluded that, “we do not know whether any one antibiotic 124 
regimen should be used in preference to another, although amoxicillin may be more 125 
effective than macrolides and cephalosporin, and should be considered as first-line 126 
treatment”. 127 
The randomized clinical trial (RCT) performed by Casey7, which was included 128 
in the BMJ review6, showed that children treated with amoxicillin/clavulanate for 10 129 
days reached “clinical cure” at 11-14 days more frequently than those treated with 130 
cefdinir for 5 days.  131 
The RCT performed by Arguedas8, which was not included in the BMJ review, 132 
focused on children with  tympanocentesis positive bacteriological cultures at 133 
baseline (54% of children), and found no differences in “clinical cure” rates at 12-14 134 
days between a single dose of azithromycin extended release and 135 
amoxicillin/clavulanate for 10 days. 136 
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A 2013 Cochrane review update9 comparing 1-2 versus 3-4 daily doses of 137 
amoxicillin (with or without clavulanate) found no new studies on this topic, and a 138 
firm conclusion could not be drawn due to limited evidence. 139 
Ototopical Symptomatic Agents 140 
The 2014 BMJ review6 found two low quality trials suggesting that topical 141 
analgesics may be more effective than placebo at reducing ear pain 10-30 minutes 142 
after administration. Another systematic review10 included the same two trials and 143 
two additional trials comparing anesthetic drops and herbal extracts drops. Again, 144 
quality of evidence was judged low, and the authors concluded that “further studies 145 
with more rigorous methodology are needed to demonstrate the utility of ototopical 146 
agents”. 147 
Systemic Steroids 148 
A 2013 systematic review11 identified a 2003 RCT comparing one 149 
intramuscular dose of ceftriaxone combined with 5 days of either oral prednisolone 150 
(and/or anti-histamine) or placebo for children with AOM. There was no significant 151 
benefit of systemic steroids. 152 
Complementary and Alternative Medicine (CAM) Treatments 153 
An RCT performed by Sinha12, at high risk of bias, compared homeopathy 154 
versus conventional treatment and found similar numbers of patients cured at 21 155 
days follow-up. 156 
At-risk Populations 157 
No new studies were found on this topic.  158 
Recurrent Acute Otitis Media (Table 2) 159 
Culture-Specific Antibiotic Treatment 160 
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Pichichero13 conducted a prospective cohort study to determine whether strict 161 
AOM diagnostic criteria, tympanocentesis and culture-specific antibiotic treatment of 162 
early life AOM episodes (individualized care) reduced the incidence of rAOM and TT 163 
placement. During 24 months follow-up, rAOM incidence and TT placement were 164 
lower in children receiving individualized care than in legacy and community controls. 165 
Surgical Treatment 166 
Kujala14 randomized children aged 10 months to 2 years with rAOM, with and 167 
without MEE at baseline, into three groups: TTs only, TTs and adenoidectomy or 168 
neither (control). Although there was a benefit of surgery over no surgery, the two 169 
surgical groups did not significantly differ with regard to number of failures for AOM 170 
recurrence and proportion of children with MEE for more than 2 months. 171 
Lous15 systematically reviewed the effectiveness of TTs in children with rAOM 172 
and included five RCTs published during 1981-1996. Because of heterogeneity, no 173 
meta-analysis was performed. Based on these trials, it was concluded that “both TT 174 
and long-term treatment with antibiotics seems to prevent one attack of AOM, or 175 
keep one child out of three free from AOM in six months”.  176 
Cheong16 conducted a systematic review of studies comparing the effect of 177 
prophylactic antibiotics, TTs and adenoidectomy on rAOM. Eighteen studies were 178 
identified, of which seven met the inclusion criteria. The authors concluded that all 179 
three treatments strategies had some benefits in preventing AOM recurrence, 180 
frequency of AOM episodes and total time spent with AOM. Based on 2 studies in 181 
children aged 1-15 years, the authors concluded that adenoidectomy was beneficial 182 
only in children over the age of 2. 183 
 Boonacker17 performed an individual patient data meta-analysis (IPDMA) of 184 
adenoidectomy for OM in children less than12 years. The authors included 15 RCTs 185 
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of adenoidectomy alone or as an adjuvant to TTs in 1761 children, and used a 186 
composite outcome including elements of both AOM and OME to summarize results. 187 
Analyzing different studies than those reviewed by Cheong16, they found that 188 
children aged less than2 years with rAOM may benefit from adenoidectomy, 189 
whereas in older children no benefit was found. 190 
CAM Treatments  191 
Marchisio18 performed an RCT evaluating the risk of rAOM in relation to 192 
Vitamin D deficiency, and whether supplementation is effective in reducing AOM 193 
recurrences in otitis-prone children. Daily administration of 1000 IU of Vitamin D for 4 194 
months during the coldest months of the year was found to reduce AOM incidence. 195 
Another RCT by Cohen19 studied the effects of pro/prebiotic-supplemented 196 
formula in infants 7-13 months old at high risk for AOM. Nasopharyngeal carriage of 197 
bacterial pathogens and AOM incidence was the same in the pro/prebiotic group and 198 
in infants who received a placebo formula.  199 
A placebo-controlled trial by Vernacchio20 found viscous xylitol solution three 200 
times daily for 12 weeks did not reduce AOM recurrences in otitis-prone infants and 201 
young children. 202 
Otitis Media with Effusion (Table 3) 203 
Oral Antibiotics 204 
 A 2012 Cochrane review and meta-analysis of RCTs of antibiotics in children 205 
with OME21 included 23 studies. The results of the review did not support routine use 206 
of antibiotics in children with OME; however, an effect on MEE clearance was seen 207 
at 1-3 months. There was no evidence of an effect of antibiotics on hearing, and 208 
none of the trials reported on speech, language, cognitive development or quality of 209 
life (QoL) outcomes. The authors emphasized that the benefits must be weighed 210 
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against the adverse effects of antibiotics for the individual and for society. One RCT 211 
of antibiotics for OME22 has been published since the Cochrane review, showing 212 
some benefit of macrolides as an adjuvant to nasal steroids over nasal steroids 213 
alone in clearing MEE, as assessed by repeated tympanometry measurements.  214 
Steroids 215 
 Since the 2011 Cochrane review on oral or topical steroids in OME cited in 216 
the previous Treatment Panel3, one additional placebo-controlled trial examined the 217 
effect of nasal steroids on OME in children with adenoid hypertrophy23; 218 
tympanometry and audiometry outcomes were better in the steroid group. One trial 219 
evaluated the effect of intra-tympanic steroid injections in adults and older children 220 
with OME24, and found some benefit on subjective symptoms and MEE. Neither of 221 
these studies reported on speech and language or other developmental outcomes.  222 
Antihistamines and Decongestants 223 
 A Cochrane review of antihistamines, decongestants and their combinations 224 
for OME was updated in 201125. While no clinical benefit was found for any of these 225 
treatments, adverse effects were more frequent than in those treated with placebo. A 226 
subsequent RCT26 of montelukast and levocetirizine for OME found improvement in 227 
otoscopic sign scores after 1 month.  228 
CAM Treatments 229 
 Fixsen27 conducted a systematic review of homeopathy in AOM and OME and 230 
found only one small study in children with OME. The author concluded that the 231 
evidence was incomplete and larger well-designed studies of CAM treatments for 232 
OM are needed.  233 
One RCT evaluated the effect of thermal therapy in children with OME28. The 234 
treatment group had better tympanometry outcomes at some of the follow-up visits.  235 
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Hearing Aids 236 
 The psychosocial impact and parental attitude to hearing aids were compared 237 
between parents of children with OME treated by TTs and those treated with hearing 238 
aids; children treated with hearing aids did not suffer the bullying nor lower self-239 
esteem anticipated by parents of children treated with TTs29.  240 
Auto-inflation 241 
 A Cochrane review of the effects of auto-inflation on OME-associated hearing 242 
loss was updated in 201330. Eight studies were included; meta-analysis showed 243 
small but positive effects of auto-inflation. The authors recommended auto-inflation 244 
during watchful waiting for OME resolution, in light of the absence of adverse effects 245 
and low cost. Since this Cochrane review, a new device for auto-inflation was tested 246 
in a small cross-over study31 on children waiting to receive TTs. Middle ear 247 
pressures continually improved, and after 8 weeks, only 4 of the 45 children received 248 
TTs.  249 
Balloon Dilatation of the Eustachian tube 250 
 Miller32 reviewed the literature on balloon dilatation of the Eustachian tube; 251 
only uncontrolled case series in adults with OME were identified, with heterogeneous 252 
data collection methods and no long-term follow-up. 253 
Tympanostomy Tubes 254 
 No new trials of TTs for OME have been published since 2011, but there were 255 
new analyses based upon existing data. Hellström33 performed a systematic review 256 
and included 63 studies. They found high level evidence of benefit of tubes for 257 
hearing and QoL for up to 9 months after treatment. 258 
 Berkman34 reviewed the literature on treatment for OME and included 59 259 
studies. They found that TTs are beneficial for clearing MEE for up to 2 years and for 260 
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improving hearing for 6 months, but found no evidence of a beneficial effect on 261 
language development.  262 
 Baik35 applied utility-based Markov decision theory modelling to the question 263 
of optimum duration of intubation with TTs. They found that intermediate-type TTs 264 
provide the greatest benefit compared to short-term TTs or permanent tubes, but this 265 
was influenced by the probability of needing a further set of TTs. Children not 266 
developing recurrent OME after a single set of TTs would be better treated with 267 
short-term tubes, but the challenge is to identify these children at first insertion.  268 
 Khodaverdi36 reported long-term outcomes of TTs in children treated with a 269 
unilateral tube for bilateral OME 25 years earlier. They found no difference in hearing 270 
thresholds between the treated and untreated ear. In contrast, a retrospective study 271 
in children diagnosed with OME 5 years earlier found that hearing was poorer in 272 
those treated with TTs compared to children who did not receive TTs37.  273 
Adenoidectomy 274 
 The previously cited IPDMA by Boonacker17 included patients with persistent 275 
OME. They found benefit of adenoidectomy in children with OME aged over 4 years, 276 
but not in younger children. 277 
Mikals38 reviewed the literature on adenoidectomy as an adjuvant to primary 278 
TT insertion. Five RCTs met the inclusion criteria; the pooled estimate of the rate of 279 
repeat TT surgeries for children undergoing primary adenoidectomy in addition to 280 
TTs was 20.4% vs 34.1% for children undergoing primary TTs only. 281 
In the TARGET RCT39, children with OME were randomized to either TTs 282 
only, adenoidectomy and TTs or watchful waiting. Adenoidectomy with TTs extended 283 
the benefit to hearing through the second year of follow-up without evident 284 
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diminution; the magnitude of this benefit was 4.2 dB HL over TTs alone. Adjuvant 285 
adenoidectomy reduced audiometric eligibility for revision surgery.  286 
In a retrospective case series of children treated with TTs, Gleinser40 found a 287 
repeat TT insertion rate of 20%. Adenoidectomy performed at the first TT insertion 288 
for OME decreased the risk of repeat TT placement, especially for children aged 4-289 
10 years. 290 
At-risk Groups 291 
 Children with cleft palate (CP) and Down syndrome (DS) are both more prone 292 
to developing OM, as well as to its complications and developmental sequelae41, yet 293 
they are excluded from most RCTs. Children with CP and DS are more likely to 294 
undergo treatment for OME, as are children with autistic spectrum disorder42. The 295 
systematic review on the effectiveness of OME treatments by Berkman34 concluded 296 
that additional research is needed to support treatment decisions in these at-risk 297 
groups. 298 
Kuo43 undertook a systematic review of TTs for OME in children with CP. 299 
They identified 9 studies of high- or moderate-quality and found short-term benefit of 300 
TTs on hearing. Tierney44 carried out a qualitative study of parents’ experiences of 301 
OME treatment in CP children and found that TTs were seen as a simple fix with 302 
some worries about complications. Hearing aids were associated with social stigma, 303 
but were well tolerated by those who wore them. 304 
 Mohiuddin45 evaluated the economic impact of TT insertion in children with 305 
OME and showed that in children with CP and bilateral OME, treatment with TTs is 306 
likely to be cost-effective. In a retrospective case series of more than 100 children 307 
with DS treated with TTs, Paulson46 found hearing did not normalize after TTs in 308 
14% of ears, signifying another underlying conductive cause or sensorineural 309 
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hearing loss. Most children (64%) had a second set of TTs, and sequelae such as 310 
chronic perforations, atelectasis and cholesteatoma were common. 311 
Tympanostomy Tube Otorrhea and Complications of Tubes (Table 4)  312 
Incidence of Tympanostomy Tube Otorrhea (TTO) 313 
Van Dongen47 used a parental web-based questionnaire to collect 314 
retrospective data on TTO incidence. In 1184 children treated with TTs aged below 315 
10 years, 52% had at least one TTO episode, 12% had recurrent TTO and 4% had 316 
prolonged TTO. Independent predictive factors for TTO were young age, rAOM as 317 
the indication for TTs, recent history of recurrent URIs and having older siblings. 318 
Treatment of TTO 319 
In an RCT, van Dongen48 compared 3 treatment modalities in children with 320 
acute TTO:  hydrocortisone-bacitracin-colistin eardrops, oral amoxicillin-clavulanate 321 
suspension or initial observation. At 2 weeks, antibiotic-steroid eardrops were more 322 
effective than oral antibiotics and initial observation in resolving otorrhea, and were 323 
most cost-effective49.  324 
Cheng50 retrospectively reviewed the management of children with methicillin-325 
resistant Staphylococcus aureus (MRSA) TTO. Of medical treatments, 326 
fluoroquinolone eardrops were most successful. In 54% of patients, TTO resolved 327 
only after TT extrusion and/or removal, with or without TT replacement.  328 
Prevention of Early Postoperative TTO 329 
 A Cochrane review51 of prevention of post-operative TTO found 15 eligible 330 
RCTs, of which 7 were considered at low risk of bias.  Four treatments were found to 331 
reduce the rate of otorrhea up to two weeks after surgery: multiple saline washouts 332 
during surgery, single application of topical antibiotic/steroid drops during surgery, 333 
prolonged application of topical antibiotic/steroid drops and prolonged application of 334 
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oral antibacterial agents/steroids. The authors concluded that if a surgeon has a high 335 
rate of postoperative otorrhea, either saline irrigation or single application of topical 336 
antibiotic drops during surgery could be an option to reduce that rate.   337 
Park52 followed 67 adult patients who received a mupirocin-coated TT and 338 
found early postoperative TTO occurred in only one patient, leading the authors to 339 
conclude that their product could be effective at preventing this problem.  340 
Complications of TTs 341 
Barati53 reviewed the medical records of all children aged 2-4 years who had 342 
TTs for OME in two hospitals. Eighty-two had otomicroscopy 10-11 years later; 343 
myringosclerosis was the most common sequela. Of note, none had developed 344 
cholesteatoma.  345 
Erdoglija54 retrospectively studied complications within 18 months after TT 346 
insertion for OME in 487 children. Common complications included transient TTO, 347 
TT obstruction and premature TT extrusion.  348 
Saki55 reviewed the medical records of 208 children followed for 12-18 months 349 
after TTs insertion for OME. “Transient” and “delayed” otorrhea occurred in 13% and 350 
8% of children, respectively. Complications after TT extrusion included atrophy, 351 
myringosclerosis and persistent perforation.  352 
Smillie56 studied complication rates after TT insertion in 60 children with cleft 353 
lip and/or palate (CLP) and in 60 matched children without.  TTO episodes were not 354 
more frequent in CLP children than in the control children. Other TT complications 355 
were more frequent in the control group. 356 
Chronic Suppurative Otitis Media (Table 5)  357 
Topical Antibiotics 358 
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Morris57 reviewed the literature on treatments for CSOM and cholesteatoma in 359 
adults and children. Although topical antibiotics seemed more effective than topical 360 
antiseptics in resolving otorrhea, the benefits of their use versus placebo in children 361 
is yet unclear.  362 
A longitudinal cohort study in Greenland looked at evolution of CSOM58. Of 363 
591 Inuit children originally examined in 1993-1994, 226 were followed up in 2009. 364 
Of 37 ears with CSOM at the initial examination, 39% had healed spontaneously.  365 
Fourteen ears not diagnosed originally with CSOM had CSOM at follow-up. One-366 
third of children had CSOM, had undergone ear surgery or had sequelae from 367 
CSOM at the follow-up visit.  368 
An RCT comparing the effects of swimming versus no-swimming in 369 
chlorinated pools in children with tympanic membrane (TM) perforations showed 370 
neither differences in proportion with discharge nor in nasopharyngeal or middle-ear 371 
microbiology of children who did or did not swim59.  372 
CAM 373 
A Cochrane review60 on the effects of zinc supplementation in preventing OM 374 
found mixed results in otherwise healthy children under 5 years living in low- and 375 
middle-income countries.  376 
Surgical Treatment 377 
  Two systematic literature reviews compared temporalis muscle fascia (TMF) 378 
to cartilage tympanoplasty61,62. Both reviews reported better structural outcomes 379 
(fewer post-operative TM perforations) with a cartilage graft, but no better functional 380 
outcomes (similar hearing). 381 
Novel Adjuvant Therapies  382 
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Hong63 reviewed various adjuvant treatments for enhancing TM perforation 383 
repair, including biomolecules to stimulate the growth of perforation edges and 384 
bioengineered scaffolds. The majority of the scaffold materials tested were safe and 385 
improved TM perforation healing rates. 386 
Kanemaru64 performed an RCT (included in Hong63) in 53 patients with 387 
chronic perforations comparing a gelatin sponge scaffold soaked in fibroblast growth 388 
factor (b-FGF) vs a gelatin sponge only following freshening of the perforation edge. 389 
They found significantly higher closure rate in the b-FGF group with no adverse 390 
events. 391 
Guidelines for Treatment of Otitis Media 392 
Acute Otitis Media and Recurrent Acute Otitis Media (Table 6) 393 
Since 2011, guidelines on the diagnosis and management of AOM have been 394 
published across the world, including the US65, Japan66,67, Korea68, the 395 
Netherlands69 and Spain70. All guidelines emphasize the need for accurate 396 
diagnosis. Pain relief is considered paramount, and watchful waiting has continued 397 
to be an option in children with “non-severe” AOM. Immediate antibiotics are 398 
reserved for children at high risk for an unfavorable outcome, with minor differences 399 
regarding definitions of “at risk” between guidelines. 400 
For rAOM, reduction of risk factors (including day care attendance and 401 
tobacco smoke exposure) is encouraged65-67, active immunoprophylaxis with 402 
pneumococcal conjugate vaccines (PCVs)65-68 and influenza vaccine65 is 403 
recommended, while long-term prophylactic antibiotics are discouraged65.  404 
Otitis Media with Effusion 405 
Guidelines on OME were published in Korea68, the US71, the Netherlands72 406 
and Denmark73.  All guidelines emphasize the importance of age-appropriate hearing 407 
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testing when the diagnosis of OME is made. Watchful waiting is recommended 408 
initially, unless the child belongs to a high-risk group or has TM morphological 409 
findings that require surgical treatment. Follow-up is recommended at 3 months with 410 
repeated hearing testing. Medical treatment is discouraged, whereas surgical 411 
intervention, TTs initially, is recommended in selected cases, considering laterality 412 
(bilateral) and duration of the disease (>3 months), hearing status (varies across 413 
guidelines from >25 to >40dB HL in the better ear), effect on the child’s wellbeing, 414 
behavior and development. The importance of involving parents in the decision-415 
making process is emphasized in all guidelines. Concomitant adenoidectomy and/or 416 
tonsillectomy are recommended only if there is concomitant upper airway disease. 417 
Audiometric surveillance every 3-6 months is recommended whenever TTs are not 418 
inserted.  419 
Impact of Guidelines 420 
A range of studies have looked at the impact of local, national and 421 
international guidelines on the treatment of AOM and URIs on clinical practice, and 422 
in particular antibiotic prescribing rates. The studies vary in their design (ranging 423 
from a survey of private physicians to analysis of regional electronic databases), 424 
study population (at-risk groups vs general population) and outcomes (ranging from 425 
diagnosis to antibiotic prescribing). Overall, adherence to published guidelines 426 
seems sub-optimal (e.g. in the UK, Italy, Sweden, Turkey, Serbia, Greece, Israel, the 427 
US)74-82. In France83, guidelines have been effective in changing the antibiotic 428 
prescribing habits of pediatricians, and in Denmark84, GPs to a large degree 429 
prescribe antibiotics appropriatelyIn the UK, the proportion of AOM episodes for 430 
which an antibiotic was prescribed was largely unchanged74, and the use of a 431 
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broader spectrum antibiotic (amoxicillin plus clavulanic acid instead of amoxicillin) 432 
was the reason for diverging from recommendations in Hungary78. 433 
In a small UK audit75, adherence to OM guidelines seems independent of 434 
medical specialty: GPs, pediatricians and otolaryngologists were equally non-435 
compliant with antibiotic guidance. In contrast, Italian pediatricians were less likely to 436 
prescribe symptom-relieving drugs, such as decongestants and mucolytics, other 437 
than antibiotics76, and Greek physicians aged below 40 years seem to adhere better 438 
to guidelines than those aged 60 years or higher79.  439 
All studies advocated continuing medical education as a means to improve 440 
the implementation of guidelines on antibiotic use; yet, the optimal method to 441 
achieve this goal is unclear. Information alone seems ineffective, which could be 442 
attributed to either the insufficient educational power of these educational 443 
interventions or other barriers to their implementation (e.g. cultural/social beliefs 444 
about the benefits and harms of antibiotics)77. Targeting specific scenarios 445 
associated with immediate vs delayed or no antibiotics prescribing for AOM, e.g. 446 
diagnosis on weekends vs weekdays, urgent care vs clinical setting, family care vs 447 
specialist care, may be effective in reducing unnecessary prescribing81. Electronic 448 
health record-based clinical decision support and performance feedback systems 449 
were found effective in improving adherence to OM guidelines; combining these two 450 
interventions, however, was no better than either delivered alone85.  451 
Complications of Otitis Media 452 
Acute mastoiditis 453 
Differing trends in acute mastoiditis (AM) incidence have recently been 454 
reported, with small series suggesting an increase86,87, while larger series suggesting 455 
no change or even a decline88-93. Many of these studies have methodological 456 
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limitations. A large US insurance claims database of children less than 6 years 457 
suggested that AM incidence has declined following the introduction of PCVs, 458 
especially PCV-1393. Nevertheless, S. pneumoniae remains the most common cause 459 
of AM across the globe86,89,91,94-104. Country-wide hospital data from Denmark and 460 
Sweden show that there has been no increase in the incidence of AM95, 102 since the 461 
introduction of guidelines to reduce antibiotic use for AOM, released a few years 462 
earlier.  463 
Several case series show that 33-81% of patients diagnosed with AM had 464 
been treated with antibiotics prior to admission, suggesting that antibiotics 465 
administered for AOM treatment do not eliminate the risk of developing this 466 
complication86,89,91,95,97-99,101,102. 467 
While AM treatment traditionally involved cortical mastoidectomy, there is a 468 
recent trend towards non-surgical management with intravenous antibiotics, either 469 
alone or combined with myringotomy and TT insertion and/or needle aspiration of the 470 
subperiosteal abscess.  Contemporary case series report mastoidectomy rates 471 
between 29-93% of mastoiditis patients; this variation may represent differences in 472 
clinical practice rather than disease severity89,90,94,95,98,99,101,102,104-106.  In a review of 473 
577 cases of AM from across Sweden, 10% of patients were successfully treated 474 
with antibiotics alone, 68% with antibiotics and myringotomy, and 22% with 475 
antibiotics and mastoidectomy102.  In Eastern Denmark95, 183/214 (86%) pediatric 476 
AM cases were treated with myringotomy and antibiotics, and 31% of them also 477 
received TT. Sixty-eight children had a subperiosteal abscess and all of these, 478 
except one, were treated by mastoidectomy. In a smaller case-series from Greece, 479 
13/24 (57%) children with a subperiosteal abscess were successfully treated with 480 
needle aspiration and myringotomy, and did not require mastoidectomy106,107.   481 
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Chesney108 developed an algorithm whereby in uncomplicated AM cases 482 
(without neurologic deficits or sepsis), computerized tomography (CT) scanning is 483 
postponed and treatment is initiated with intravenous antibiotics, with or without 484 
myringotomy and/or drainage or aspiration of any subperiosteal abscess. Failure to 485 
improve after 48 hours or clinical deterioration should prompt a CT scan to assess 486 
coexistent intracranial pathology, followed by mastoidectomy. 487 
Intracranial Complications 488 
Retrospective reviews show that brain abscess is the most common 489 
intracranial complication of OM104,109,110, with an estimated incidence of 1 per million 490 
per annum111. A small Israeli case-series found no reliable clinical signs or 491 
symptoms to distinguish children presenting with AM and coexistent intracranial 492 
complications from those without, confirming that imaging is warranted in cases not 493 
resolving promptly with conservative measures112. 494 
The role of anticoagulation in otogenic sigmoid sinus thrombosis remains 495 
controversial. Au113 reviewed the literature, and found that anticoagulation was 496 
employed in 39/68 (57%) cases; 84% achieved partial or complete recanalization.  497 
However, 3/4 (75%) patients not treated with anticoagulation also achieved partial or 498 
complete recanalization. Reviews by Cochrane114 and by the European Pediatric 499 
Neurology Society115 found no RCTs of treatments of cerebral venous sinus 500 
thrombosis; both concluded that in the absence of contraindications, anticoagulation 501 
seems a safe and reasonable treatment114,115. Several retrospective reviews report 502 
no complications of anticoagulation in patients with otogenic sinus thrombosis116-121. 503 
  504 
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IMPLICATIONS FOR PRACTICE 505 
While there were no studies that revolutionized treatment of OM in its various 506 
forms, the recent literature refines our knowledge of the effectiveness, and lack 507 
thereof, of various treatments.  Accurate diagnosis of OM, in its various forms, and 508 
optimal management of ear pain is key to reducing over-diagnosis and over-509 
treatment of this common condition in children. While antibiotics do shorten 510 
symptoms and duration of middle ear effusion, it is important to weigh their benefits 511 
and harms in OM. Watchful waiting is optional in mild to moderate AOM. 512 
Symptomatic hearing loss with OME is best treated with tympanostomy tubes. The 513 
benefit from adenoidectomy in OM is controversial and age-dependent. Topical 514 
antibiotics are the treatment of choice in acute tube otorrhea. Novel molecular and 515 
biomaterial treatments as adjuvants to surgical closure of eardrum perforations are 516 
promising. There is insufficient evidence to support the use of CAM.  517 
 From this review of the literature, it was apparent to the panel members that 518 
high quality studies of OM treatments are needed in children particularly at risk for 519 
OM and its complications, as such children have so far been excluded from most 520 
research.  521 
 522 
  523 
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Table 1: AOM Studies (Antibiotic Treatments)  
Author, 
Year 
Type 
No. of Participants, 
Setting 
Intervention 
(participants) 
Comparator 
(participants) 
Main Outcomes 
Effect Estimates 
(95%CI) 
Tapiainen, 
20141 
RCT 84 (1), 
primary care 
Amox-clav, 7d  
(42) 
Placebo  
(42) 
Time to MEE disappearance 18.9d vs 32.6d; 
p=.02. 
Normal tympanometry at 14d 29/42 vs 16/42; 
p<.01; NNTB: 4. 
Venekamp, 
20152 
SR 3401 (12), 
primary + secondary 
care 
Oral antibiotics Placebo Pain at 2-3d RR 0.7 (0.6-0.9); 
NNTB: 20. 
Adverse effects RR 1.3 (1.2-1.6); 
NNTH: 14. 
Casey,  
20123 
RCT 330 (1), 
secondary care 
Amox-clav, 10d 
(165) 
Cefdinir, 5d 
(165) 
Clinical cure at 11-14d 141/165 vs 
115/165; p<.01. 
Arguedas, 
20114 
RCT 923 (1), 
secondary care 
Azithromycin ER, 
single dose (462) 
Amox-clav, 10d 
(461) 
Clinical cure at 12-14d 207/258 vs 
202/239; p=.24. 
Clinical cure at 41-64d 74/79 vs 60/66; 
p=.55. 
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Amox-clav: amoxicillin-clavulanate; CI: confidence interval; d: days; ER: extended release; MEE; middle ear effusion; NNTB: number needed to 
treat to benefit; NNTH: number needed to treat to harm; RCT: randomized controlled trial; RR: relative risk; SR: systematic review 
1Amox-clav: 40 mg/kg/d amoxicillin. 
2Reported results for pain at 2-3d correspond to 138/1186 and 180/1134 children (7 studies) in the oral antibiotics and placebo groups, 
respectively, and for adverse events to 283/1044 and 208/1063 children (8 studies) in the oral antibiotics and placebo groups, respectively. 
3Amox-clav: 80 mg/kg/d amoxicillin; cefdinir: 14 mg/kg/d. 
4Azithromycin ER: 60mg/kg; amox-clav 90mg/kg/d amoxicillin. Reported results are for 258 and 239 children with available bacteriological studies 
in the azithromycin ER and amox-clav groups on the test-of-cure days (12-14d), respectively, and for 79 and 66 children with available 
bacteriological studies in the azithromycin ER and amox-clav groups in the end of the study period (41-64d), respectively.   
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Table 2: RAOM Studies 
Author,  
Year 
Type 
No. of 
Participants 
Intervention Comparator Main Outcome(s) Effect Estimate(s) 
Pichichero 
2013 
Cohort 1482 Individualized 
care (254) 
Legacy controls (208); 
Community controls 
(1024)  
rAOM incidence 6% vs 14% vs 27%; 
p<.0001. 
TTs incidence 2% vs 6% vs 15; 
p<.0001. 
Kujala 
2012 
RCT 300 TTs+Ad (100),               
TTs (100) 
Controls (100)  Treatment Failure:  
2 AOMs in 2 mos, 
3 AOMs in 6 mos or 
MEE >2 mos 
TTs 21%,TTs+Ad 16%, 
controls 34%. TTs vs 
controls: -13% [95%CI:-
25%-(-1%), 
p=.04].TTs+Ad vs 
controls: -18% [95%CI: -
30%-(-6%), p=.004].  
Treatment Failure 
reduction 
TTs 38%, TTs+Ad 53%. 
Lous 
2011 
SR 5 studies, 
519  
TTs (235) Observation,  
ABx,  
placebo (284) 
Prevention of AOM in 
6 mos 
2-5 children need to be 
tubed to prevent 1 child 
from AOM attacks. 
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Prevention of AOM 
during 6 mos after 
TTs placement 
TTs prevent 1 AOM 
attack. 
Cheong  
2012 
SR 7 studies, 
>1300 
Prophylactic 
ABx, 
TTs, 
Ad 
Observation,  
placebo,  
ABx  
 
 
AOM recurrence 
Frequency of AOM 
Total time with AOM 
Prop. ABx     TT         Ad 
     +                -             + 
     +                +            + 
     +                +            - 
Boonacker 
20141 
Meta-
analysis 
10 studies, 
1761 
Ad (with or 
without TTs) 
TTs, observation Failure at 12 mos, 
stratified according to 
age, baseline disease  
Ad 56%. 16% of children 
<2 years with rAOM and 
had Ad failed, vs 27% of 
those who did not have 
Ad failed. RD -12%, 
95%Cl: 6% to 18%. 51% 
of children ≥4 years with 
OME and had Ad failed, 
vs 70% of those who did 
not have Ad. RD -19%, 
95%Cl: 12%-26%. 
Marchisio RCT 116 Vitamin D, Placebo (58) >  1 AOM(s) in 7 mos 26 vs 38, p=.03. 
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2013 1000 IU/d  (58) Mean AOM 
episode(s) in 7 mos 
0.7±0.8 vs 1.4±1.4, 
(p=.003). 
Cohen 
2013 
RCT 224 Pro/Prebiotic 
enriched 
formula (112) 
Follow-up formula (112) No. of AOM 
episode(s) in 12 mos 
IRR 1.0; 95%CI: 0.8-1.2 
(p=.797).  
rAOM OR =1.0; 95%CI: 0.5-1.7 
(p=.889). 
Vernacchio 
2014 
RCT 326 Xylitol (160) Controls (166) AOM incidence/90d 0.53 vs 0.59,  
95%CI: -0.25-0.13. 
Time to first AOM in 
90d 
HR: 0.93, 
 95% CI: 0.56-1.57. 
Total days with ABx 
in 90d 
6.8d vs 6.4d, 
 95%CI: -1.8-2.7. 
 
ABx, antibiotic therapy; Ad: adenoidectomy; AOM, acute otitis media; CI: confidence interval; d: day; HR: hazards ratio; IRR: incidence rate ratio; 
IU: international units; MEE: middle ear with effusion; mos, months; OR: odds ratio; rAOM, recurrent acute otitis media; RCT: randomized 
controlled trial; RD: rate difference; SR: systematic review; TT: tympanostomy tube 
1In this trial, eligible studies for inclusion in this meta-analysis were randomized controlled trials in children up to 12 years of age diagnosed with 
recurrent AOM and/or persistent OME in which adenoidectomy (with or without tympanostomy tubes) was compared to non-surgical treatment or 
grommets alone.  
45 
 
 
Table 3: OME Studies 
Author, 
Year 
Study 
Type 
No. of 
Participants 
Intervention Primary Outcome Results (95%CI) 
Van Zon 
20121  
Cochrane/ 
meta-
analysis 
23 studies, 
3027  
ABx vs no 
treatment or 
placebo 
MEE complete 
resolution at 2-3 mos 
Improvement in 1% (-0.11-0.12) to 45% 
(0.25-0.65) of children receiving ABx. 
Chen, 20132 RCT 84 (73 
completed) 
Macrolides (36) 
vs nasal steroids 
(37) 
MEE clearance at   
8-12 weeks (%)   
38 vs 19, 70 vs 25, and 80 vs 26, after 8, 
10 and 12 weeks, respectively. 
Bhargava 
2014 
RCT 62  Mometasone (30) 
vs saline (32) 
MEE resolution at  
24 weeks 
 93% vs 50%, p=.0004. 
Yang  
2014 
RCT 90  
(112 ears) 
Intra-tympanic 
injection with 
budesonide (30), 
dexamethasone 
(31) or saline (29) 
Improvement of 
subjective 
symptoms, on a 10-
point visual scale 
Budesonide vs saline, RR 0.139 (0.054-
0.358); Dexamethose vs saline,  RR 0.485 
(0.240-0.979)  
Efficacy at 8 and 16 
weeks 
Budesonide: 95%, 90%; Dexamethasone: 
75%, 55%; Saline: 40%, 20%. 
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Griffin  
2011 
Cochrane/ 
meta-
analysis 
16 studies, 
1880 
Anti-histamines, 
decongestants, 
combinations  
Resolution of MEE 
at 1 mo 
RR 0.99 (0.92-1.05) for all interventions. 
Ertugay  
 
2013 
RCT 120 Montelukast vs 
levocetirizine vs 
both vs placebo 
Otoscopic scores 
improvement, at 1 
mo 
Both montelukast and levocetirizine: 
greater improvement in scores than all 
other groups, p<.05. Multiple risk 
differences, 0.6-10.0. 
Fixsen  
 
2013 
 
SR - Homeopathy MEE improvement  Insufficient evidence. 
Califano  
 
2014 
RCT 80  Oral steroids vs 
thermal therapy 
(sulphur water) 
Tympanogram type 
improvement at 
various time points 
Thermal therapy group had better 
tympanograms, sometimes reaching 
statistical significance. 
Qureishi  
 
20143 
 
Cross-
sectional  
97  HAs vs TTs Psychosocial impact 
difference of HAs  
Families with HAs rating higher marks than 
families without HAs (p<.05).   
Perera  
 
2013 
Cochrane 
review /  
meta-
analysis 
8 studies, 
702 
Auto-inflation vs 
no treatment 
Tympanogram 
improvement; >10dB 
improvement in 
hearing level; both 
No effect on individual measures. For 
composite measure >1 mo., RR 1.74 (1.22 
2.50).  
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Bidarian-
Moniri  
 
2014 
Cross-over 
study 
45 New device for 
auto-inflation vs 
no treatment for 4 
weeks, then 
treatments cross-
over between 4th-
8th weeks 
Middle ear pressure 
improvement at 4 
and 8 weeks 
At 4 weeks: improvement by 166 daPa 
(treatment) and 19 daPa (control), p<.0001. 
At 8 weeks: improvement by 187 daPa (in 
group having received treatment, p<.0001. 
Improvement in 
hearing at 4 and 8 
weeks. 
At 4 weeks: mean hearing levels improved 
by 6dB (p<.0001) vs 1dB, p<0.0001. At 8 
weeks: unchanged and improved by 7 dB.  
Miller 
 
20134 
SR 5 studies, 
375 
Balloon dilatation 
of the Eustachian 
tube (surgery) 
Normalization of 
tympanometry  
69/89 (78%) abnormal tympanograms (type 
B/C) normalized to post-operative type A. 
Normalization of 
otoscopic findings  
40/46 (87%) pre-operative abnormal 
findings normalized post-operatively.  
Hellström  
 
2011 
SR 63 studies, 
11 on OME 
(1756); QoL 
studies 
Bilateral TTs vs 
WW; unilateral 
TT vs no 
treatment  
TTs effectiveness, 
assessed by QoL, 
hearing, language, 
and rAOM frequency 
Hearing levels improved significantly with 
TTs, no clear effects on language, some 
evidence of TTs improving QoL. 
Berkman  
 
2013 
Meta-
analysis 
59 studies WW, TTs, Ad, 
myringotomy, 
auto-inflation, oral 
or nasal steroids, 
OME improvement, 
hearing 
improvement, 
complications,  
Length of TT retention corresponded to TT 
type. TT type was not related to improved 
OME and hearing outcomes. TT decreased 
OME for 2 years compared to WW or 
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complementary 
medicine 
myringotomy, and improved hearing for 6 
months compared to WW. OME resolution 
was more likely with Ad.   
Baik  
 
2015 
Markov 
decision 
analysis 
Hypothetical 
cohort 
Short-, 
intermediate- and 
long-term TTs 
Complications of 
TTs in 2, 4 and 6 yrs 
(total utility) 
Intermediate-term TTs: 2.48, 3.96, 5.27, 
superior to short-term TTs (2.32, 3.82, 
5.18) and long-term TTs (2.42, 3.86, 5.18).  
Khodaverdi  
 
2013 
LFS 104 TT-treated ear to 
non-treated ear in 
the same patient 
Difference in hearing 
thresholds 
No significant difference. 
MRC Otitis 
Media Study 
Group  
 
2012 
RCT 376 WW vs TTs only 
vs TTs+Ad 
Hearing thresholds, 
revision surgery, 
otoscopic sequelae 
and Ad 
complications 
Ad did not add to the benefit of TTs before 
6 mos: 8.8 dB (7.1-10.5); for longer 
observation, it conferred 4.2 dB benefit 
(2.6-5.7), compared to none for TTs. For 
re-TT, RR=3.2 (1.8-5.9). 
Gleinser  
 
2011 
 
RS 904 TTs+Ad vs TTs Re-TTs rate Re-TTs rate: 7% vs 20%, p=.0001. 
Hong  
 
2015 
RS  
follow-up  
89  Children with 
OME who had no 
Hearing thresholds 
differences (dB) 
No surgery: 10±6.5, TTs once: 15.9±11.2; 
>1 set of TTs: 17.8±7.6.   
No surgery vs rest, p<.005. 
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surgery, 1 set of 
TTs, and TTs>1 
Kuo  
 
2014 
SR 9 studies, 
702 
TTs vs 
observation in 
children with CP 
Effectiveness of TTs 
on hearing and 
speech  
TTs have a beneficial effect on hearing in 
the short term; long-term effects are still 
unknown. Positive effect on speech. 
Tierney  
 
2013 
Qualitative 
study 
37 parents 
of CP 
children 
Interviews with 
parents on TTs 
vs HAs 
Parents' experiences  TTs: “quick-fix”, but some had concerns 
about complications. HAs: possible social 
stigma, but tolerated them well if worn. 
Paulson  
 
2014 
RS  102 Children with DS 
receiving TTs 
Hearing results, no. 
of TT operations, 
long-term 
complications 
Most patients had normal post-operative 
hearing. Most had ≥2 TT sets. Long-term 
complications increased with the number of 
TT sets. 
Wang  
 
2014 
RS 1755  TTs+Ad vs TTs Re-TTs rate Re-TT rate: 5.1% vs 9%, p=.002.  Ad effect 
more obvious >4 years. Controlled for age, 
RR: 0.60 (0.41–0.89). 
ABG: air-bone gap; ABx, antibiotic therapy; Ad: adenoidectomy; amox-clav: amoxicillin-clavulanate;  CI: confidence interval; CP: cleft palate; DS: 
Down's children; HA: hearing aids; LFS: Longitudinal follow-up study; MEE: middle ear effusion; mo: month; OME: otitis media with effusion; QoL: 
quality of life; RAOM: recurrent acute otitis media;  RCT: randomized controlled trial; RR: relative risk; RS: retrospective; SR: systematic review; 
TT: tympanostomy tube; WW: watchful waiting; yrs; years.    
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1Numbers are shown for studies who tested normalization of tympanometry profiles and otoscopy findings.2Clarithromycin: 15 mg/kg/d bid daily in 
the first week, then changed to a low dose, 5-8 mg/kg/d qd, until the tympanogram was type “A”. 3Qualititive cross-sectional study. Parents of 
children with hearing aids filled the questionnaires. 4Only 5 case-series studies fullfilled enrollment criteria for this systematic review. 
Table 4: Otorrhea Studies 
Author, Year Type 
Population,  
No. of Participants 
Main Outcome(s) Results (95%CI) 
van Dongen 
2013 
RS  
Children <10 yrs with TTs 
(1184) 
TTO incidence  
52% had ≥1 episode(s) of TTO: 12% had 
TTO within the calendar month of TT 
placement. 50% had ≥1 acute TTO episodes, 
4% had ≥1 chronic TTO episode(s), and 12% 
had recurrent TTO episode(s). 
van Dongen 
2014, 2015 
Open label 
RCT 
230 Children aged 1-10 yrs 
with acute TTO: 
hydrocortisone-bacitracin-
colistin eardrops (76), oral 
amox-clav suspension (77), 
observation (77) 
TTO at 2 weeks 
5% eardrops treated, 44% amox-clav treated, 
risk difference, -39% [-51-(-26)], 55% 
observed, risk difference, -49%; [-62-(-37)]. 
Mean total cost/patient at 
2 weeks and at 6 mos 
2 weeks: US$42.43 for eardrops, US$70.60 
for oral antibiotics, and US$82.03 for initial 
observation. At 6 mos: US$368.20, 
US$420.73, and US$640.44, respectively 
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Cheng  
2012 
RS 
Children <18 yrs with MRSA-
positive TTO (41) 
ABx resistance patterns 
and treatment success 
rates 
Fluoroquinolones and clindamycin resistance 
in 88% and 61% of cases. Ototopical 
fluoroquinolone and sulfacetamide were 
associated with successful TTO resolution, 
p=.005, p=.009.  
Park  
2012  
RS 
67 children  with mupirocin-
coated TTs (98 ears) 
Post-operative TTO 
incidence (at 2 weeks) 
1 (1.5%) case had post-operative TTO with 
experimental TT.  
Barati  
2012 
LFS 
10-11 yrs FU of children who 
underwent TTs at 2-4 yrs 
(82) 
TT complication rate 
Myringosclerosis, 17.1%; TM atrophy, 1.2%; 
permanent TM perforation, 0.6%; TM 
atelectasis 0.6%;  cholesteatoma 0%. 
Erdoglija 
2012 
RS 
478 children who were 
treated with TTs (843 ears) 
TTs complication rate  
at 12-18 mos FU 
Transient TTO: 16.5%, TT obstruction: 9.5%, 
premature extrusion: 3.9%, chronic TTO: 
3.1%, granulation tissue: 1.1% 
Saki  
2012 
Prospective  
Children aged 10 mos-6 
years with TTs (208) 
Post-operative TTO 
incidence, post-extrusion 
complications rate 
At 12-18 mos FU: transient TTO: 12.5%; 
delayed TTO: 8.2%. Complications after TT 
extrusion: atrophy: 27.8%; myringosclerosis: 
37.9%; persistent TM perforation: 2.4%. 
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Smillie 
 2014 
Case-
control  
60 children with CLP who 
underwent TTs, vs age- and 
sex-matched controls  
TTO incidence 
Controls had 151 cases of TTO, compared to 
121 in the CLP group (ratio 1.25:1). 
Difference was not significant (p = .52).  
 
Amox-clav: amoxicillin-clavulanate; CLS: cleft lip and palate; FU: follow up; mos: months; LFS: longitudinal follow-up study; MRSA: methicillin-
resistant Staphylococcus aureus; RS: retrospective study; TM: tympanic membrane; TT: tympanostomy tube; TTO: tympanostomy tube otorrhea; 
yrs: years 
Table 5: CSOM Studies 
Author, 
Year 
Type 
Population,  
No. of 
Participants 
Intervention Comparator Results (95%CI) 
Morris 
2012 
 
SR 
 
Children and 
adults with 
CSOM,  
51 studies  
Topical ear cleansing, surgery for 
cholesteatoma, systemic ABx, topical ABx 
topical ABX plus topical corticosteroids, 
topical antiseptics, topical corticosteroids, 
tympanoplasty 
Various 
Children: topical antibiotics may improve 
Sx, compared to antiseptics. Other 
topical treatments are not superior to 
placebo. Adults: topical antibiotics 
alone/with topical corticosteroids may 
improve Sx, compared to placebo or 
either treatment alone.  
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Jensen 
2012 
LFS 
226 children 
seen at  
10-12 yrs FU 
Spontaneous healing of the TM - 
591 children initially examined. TM 
spontaneous healing: 39%; Overall 
CSOM prevalence: 9%. 
Stephen  
2013 
RCT 
89 children 
with CSOM 
Swam in chlorinated pool (41) Did not swim (44) 
No significant changes in the 
nasopharynx or middle ear microbiology. 
Gulani  
20141 
SR 
10 studies,  
6820 
children 
Zinc supplements, at any dose, given at 
least once a week, for at least one month 
Placebo 
One old trial found benefit in treating 
children with severe malnutrition, and 
correlated lower levels of minerals and 
vitamin D with CSOM severity.  
Iacovou  
2013 
SR 
12 studies,  
1286 
patients 
CR TMF 
Mean graft integration rate: CR 92.4% vs 
TMF 84.3%. 
CR promoted better ABG closure (p<.05). 
Mohamad 
2012 
SR 
14 studies,  
1475 
patients 
Tympanoplasty with CR 
Tympanoplasty with 
TMF  
Revision rate: CR: 10% vs TMF: 19%. 
Statistically significant better morphologic 
success with CR. No significant 
differences regarding hearing outcome.  
Hong  
2013 
SR 26 studies 
Tympanoplasty grafts made with 
biomolecules (platelet-derived growth 
factor, platelet-rich plasma, hyaluronic acid, 
epidermal growth factor and pentoxifylline, 
TMF or no material 
Several studies demonstrated positive 
results. Many questions still remain, such 
as the adequacy of animal models and 
long-term biocompatibility of adjuvant 
materials.  
54 
 
 
b-FGF, combinations) and scaffolding 
materials (i.e., alloderm, silk patches) 
Kanemaru 
2011 
RCT 63 patients TEM, b-FGF (53) TEM, saline (10) 
TM closure rate: 98.1% vs 10%. Average 
hearing was improved. No serious 
sequelae were reported. 
ABG: air-bone gap; ABx: antibiotic therapy;  b-FGF: basic  fibroblast growth factor; CI: confidence interval; CSOM: chronic suppurative otitis 
media; CR: cartilage reconstruction; FU: follow up; LFS: Longitudinal follow-up study; OR: odds ratio; PTF: temporalis fascia; RCT: randomized 
controlled trial; RS: Retrospective study; SR: systematic review;  Sx: symptoms; TEM: tissue engineered myringoplasty; TM: tympanic membrane; 
TMF: temporalis muscle fascia; vs: versus; Zn, zinc 
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Table 6:  Selected National Guidelines for AOM  
Country Age  Diagnosis/Instruments Management First-line Antibiotics1  
USA,  
2013 
 
6 mos- 
12 yrs 
Stringent criteria.  
Key factors: TM bulging or new-
onset otorrhea. Use of pneumatic 
otoscopy and tympanometry.  
Treat pain. 
ABx: children ≥6 mos with severe AOM, 
non-severe bilateral AOM in children 6-
23 mos. WW: non-severe unilateral 
AOM in children <23 mos, non-severe 
AOM in children >24 mos.  
High dose amox; High dose 
amox-clav in children 
receiving amoxicillin in the 
previous 30 days or with 
otitis-conjunctivitis. 
Japan,  
2013 
0-15 yrs Accurate diagnosis. Otomicroscopy 
or otoscopic observation. 
Pneumatic otoscopy acceptable. 
Mild AOM:  3 days WW, otherwise ABx. 
Moderate AOM: immediate ABx.  
Severe AOM: myringotomy and ABx. 
Low dose amox→ high 
dose amox→ amox-clav or 
ceftidoren pivoxil.    
South Korea,  
2012 
0-15 yrs Definitive (Sx and TM findings) vs 
suspicious (Sx without objective 
findings) diagnosis  
WW: possible, FU visit after 2-3 days.   
ABx: severe AOM, <6 mos, 6-24 mos 
with definite AOM, when FU is 
impossible, co-morbidities. 
High dose amox; 
Severe AOM: high dose 
amox-clav. 
The 
Netherlands, 
2014 
0-18 yrs Patient's history, Sx and otoscopy 
findings. Treat pain.  
Immediate ABx: infants <6 mos, severe 
AOM. Consider ABx: children <2 years 
& bilateral AOM, otorrhea, persisting Sx.  
Low dose amox.   
Amox-clav if no 
improvement after 48 hours  
ABx: antibiotic therapy; amox: amoxicillin; amox-clav: amoxicillin-clavulanic acid; AOM, acute otitis media; mos: months; FU: follow up; MEE: 
middle ear effusion; rAOM, recurrent otitis media; Sx: symptoms; TM: tympanic membrane; WW: watchful waiting; yrs, years 
 1High dose amoxicillin/amox-clav: 80-90mg/kg/d of amoxicillin; low dose amoxicillin: 40mg/kg/d of amoxicillin 
